Diabetes Mellitus — Clinical Documentation Guide (2026)

🔍 1. Definition

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The condition encompasses a spectrum of pathophysiologic processes ranging from absolute insulin deficiency (Type 1) to progressive insulin secretory failure superimposed on insulin resistance (Type 2). Per the American Diabetes Association (ADA) Standards of Care in Diabetes—2026, diagnosis is confirmed by one of four criteria: fasting plasma glucose ≥126 mg/dL, 2-hour plasma glucose ≥200 mg/dL during a 75-g OGTT, A1C ≥6.5% (using an FDA-approved CLIA-certified method), or a random plasma glucose ≥200 mg/dL in a patient with classic hyperglycemia symptoms.

Diabetes mellitus is classified in categories E08–E13 of Chapter 4 (Endocrine, Nutritional and Metabolic Diseases) of the ICD-10-CM FY2026 Tabular List. The classification has two primary axes: (1) the type or etiology of diabetes (the category), and (2) any associated complication (4th/5th/6th character extensions). The essential element in code selection is the type of diabetes — not whether the patient uses insulin per ICD-10-CM coding guidance (AAPC).

From a population health standpoint, the CDC estimates that more than 38 million Americans (11.6% of the population) have diabetes, and approximately 90–95% of cases are Type 2. Diabetes is the leading cause of new blindness in adults, end-stage renal disease, and non-traumatic lower limb amputation — making precise clinical documentation and coding directly impactful on care management and risk adjustment.

🗂️ 2. Alternative Terminology

Clinicians, nurses, and patients use a wide variety of terms when referring to diabetes mellitus. Coders must recognize these lay, colloquial, and clinical synonyms to accurately abstract diagnoses from provider documentation.

🩺 3. Signs & Symptoms

Clinical presentation varies significantly by diabetes type, duration, and degree of glycemic control. Coders should not code signs and symptoms that are integral to a confirmed diabetes diagnosis (per ICD-10-CM guideline I.C.4), but they must recognize presentations that prompt CDI queries for new complications.

Classic hyperglycemic symptoms:

• Polydipsia (excessive thirst)
• Polyuria (frequent urination) and nocturia
• Polyphagia (excessive hunger) with unexplained weight loss (Type 1)
• Blurred vision (osmotic lens changes)
• Fatigue, weakness, malaise
• Slow wound healing; recurrent infections (UTI, yeast, skin)

Acute complications:

• Diabetic ketoacidosis (DKA): nausea, vomiting, abdominal pain, Kussmaul respirations, fruity breath, altered mental status
• Hyperosmolar hyperglycemic state (HHS): profound dehydration, neurological deficits, glucose typically >600 mg/dL without significant ketosis
• Hypoglycemia: diaphoresis, tremor, palpitations, confusion, seizures, loss of consciousness

Chronic complication signs:

• Renal: proteinuria, edema, hypertension, progressive azotemia
• Ophthalmic: microaneurysms, cotton wool spots, retinal hemorrhages, neovascularization, macular edema
• Neurological: distal symmetric polyneuropathy (burning, numbness, stocking-glove distribution), autonomic neuropathy (gastroparesis, orthostatic hypotension, neurogenic bladder), Charcot joint
• Circulatory: peripheral arterial disease (claudication, absent pulses), coronary artery disease, stroke
• Dermatological: necrobiosis lipoidica diabeticorum, diabetic dermopathy, acanthosis nigricans
• Oral: periodontal disease, xerostomia

🧭 4. Differential Diagnosis

The differential for new-onset hyperglycemia or a suspected diabetes diagnosis is broad. Establishing the correct diabetes type and etiology is critical for accurate ICD-10-CM category selection.

📋 5. Clinical Indicators for Coders/CDI

The following clinical findings in the medical record should prompt coders and CDI specialists to query for additional specificity or linkage of diabetes complications.

🦴 6. Anatomy & Pathophysiology

The Pancreas and Insulin Regulation: The islets of Langerhans in the pancreatic parenchyma contain beta cells (insulin-secreting), alpha cells (glucagon-secreting), and delta cells (somatostatin-secreting). In health, postprandial glucose elevation triggers pancreatic beta-cell insulin secretion in a biphasic pattern, facilitating glucose uptake in skeletal muscle, adipose tissue, and hepatic suppression of gluconeogenesis.

Type 1 DM Pathophysiology: An autoimmune T-cell–mediated destruction of pancreatic beta cells results in absolute insulin deficiency. Triggers include genetic susceptibility (HLA-DR3/DR4) and environmental factors (viral infections, gut microbiome alterations). With >80–90% beta-cell loss, hyperglycemia becomes manifest. Without insulin, ketogenesis is uninhibited, resulting in the characteristic DKA risk. Per ADA 2026 Standards of Care, patients with presymptomatic Type 1 DM (stage 1–2) may be identified by autoantibody screening before frank hyperglycemia occurs.

Type 2 DM Pathophysiology: T2DM involves the interplay of insulin resistance (primarily at skeletal muscle, liver, and adipose tissue) and progressive beta-cell secretory failure. The “ominous octet” (Defronzo model) includes: decreased muscle glucose uptake, increased hepatic glucose output, impaired incretin effect, alpha-cell hyperglucagonemia, increased renal glucose reabsorption (SGLT-2 upregulation), increased lipolysis (adipose), decreased central satiety signaling, and decreased beta-cell insulin secretion. Chronic hyperglycemia accelerates all complications via oxidative stress, advanced glycation end products (AGEs), and the polyol pathway.

Secondary DM (E08): Conditions that destroy pancreatic tissue (chronic pancreatitis, cystic fibrosis, hemochromatosis, pancreatic cancer) or cause hormonal insulin antagonism (Cushing syndrome — cortisol excess; acromegaly — GH excess; pheochromocytoma — catecholamine excess; glucagonoma) can cause secondary DM. The underlying condition is sequenced first per ICD-10-CM guidelines.

Chronic Complication Mechanisms: Sustained hyperglycemia damages small vessels (microvascular disease) via multiple mechanisms including AGE accumulation, protein kinase C activation, and hexosamine pathway flux. Macrovascular complications (CAD, stroke, PAD) result from accelerated atherosclerosis driven by dyslipidemia, inflammation, and oxidative stress. Neuropathy involves both microvascular nerve ischemia and direct Schwann cell/neuronal glucose toxicity.

💊 7. Medication Impact / Treatment

The pharmacological landscape for diabetes management has expanded significantly, and medication documentation critically affects ICD-10-CM secondary code assignment and HCC risk adjustment. Per ADA 2026 Standards of Care, treatment is individualized based on A1C targets, comorbidities (CVD, CKD, heart failure), hypoglycemia risk, weight effects, cost, and patient preference.

Oral Agents (assign Z79.84):

• Metformin: First-line agent; biguanide class; hepatic glucose suppression and insulin sensitization; associated with B12 deficiency with long-term use (per ADA 2026, monitor B12 periodically)
• SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin): Glucosuria mechanism; cardiovascular and renal protective benefits in T2DM; preferred with heart failure or CKD per ADA 2026
• Sulfonylureas (glipizide, glimepiride, glyburide): Stimulate insulin secretion; hypoglycemia risk; weight gain
• DPP-4 inhibitors (sitagliptin, linagliptin): Incretin-based; weight neutral; renal dosing adjustments required
• Thiazolidinediones (pioglitazone): Insulin sensitizer; beneficial in MASLD per ADA 2026; risk of edema, fractures, bladder cancer

Non-Insulin Injectable Agents (assign Z79.85):

• GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, tirzepatide [dual GIP/GLP-1]): Cardiovascular and renal protective; preferred with established CVD or high CVD risk; weight reduction; semaglutide injectable coded J3590 (unclassified) per HCPCS; oral semaglutide assign Z79.84
• Amylin analogues (pramlintide): Adjunct to insulin; slows gastric emptying

Insulin Therapy (assign Z79.4 for T2/E08/E09/E13 patients):

• Basal insulins: Insulin glargine, detemir, degludec; once-daily dosing for basal coverage
• Bolus/prandial insulins: Insulin lispro, aspart, glulisine; pre-meal rapid-acting coverage
• Premixed insulins: Fixed combinations of basal/bolus
• Insulin pumps (CSII — continuous subcutaneous insulin infusion): HCPCS E0784; K0601-K0605 batteries; CGM integration (sensor-augmented pumps)

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO CDG members.

📘 8. ICD-10-CM Guidelines (FY2026)

All diabetes mellitus coding is governed by ICD-10-CM Official Guidelines for Coding and Reporting FY2026, Section I.C.4 (Endocrine, Nutritional, and Metabolic Diseases). The following rules are essential:

I.C.4.a — Diabetes Mellitus Coding Guidelines

I.C.4.a.1 — Identifying the Type: The type of diabetes mellitus is the primary determinant of category selection (E08–E13). When the type is not documented, default to Type 2 (E11) per guideline. Insulin use alone does NOT determine Type 1 — many T2DM patients require insulin.

I.C.4.a.2 — Assigning Diabetes Codes and Sequencing:

• E08 (DM due to underlying condition): Sequence the underlying condition FIRST (e.g., cystic fibrosis, Cushing syndrome), then E08.x. Use “use additional code” instruction for complications.
• E09 (Drug/chemical-induced DM): Sequence E09.x FIRST, then assign the adverse effect code (T36–T50 with 5th/6th character 5) to identify the causative drug. Note: Under HCC v28, all E09 codes have been removed from the risk adjustment model per DoctusTech HCC V28 analysis.
• E10 (Type 1 DM): Do NOT assign Z79.4 with E10 — insulin use is inherent to Type 1 diabetes per ICD-10-CM tabular instructions.
• E11 (Type 2 DM): Assign Z79.4 when insulin is used; Z79.84 for oral agents; Z79.85 for injectable non-insulin agents. When both insulin and oral agents are used, assign only Z79.4.
• E13 (Other specified DM): Includes post-pancreatectomy, postprocedural, monogenic (MODY), and secondary DM NEC. Use same complication extension logic as E10/E11.

I.C.4.a.3 — Long-term Insulin Use with Type 2 DM: Per the AHA Coding Clinic guidance reinforced through 2025, when a provider documents that a Type 2 diabetic patient receives long-term insulin, assign Z79.4 as an additional code. This is a critical HCC documentation opportunity — it confirms the complexity of management and supports audit documentation.

I.C.4.a.4 — Diabetic Complications and the “With” Convention: Per ICD-10-CM Guideline I.A.15, the word “with” in the Alphabetic Index or Tabular List establishes a presumed causal relationship between diabetes and listed conditions. This means coders do NOT need explicit provider linkage for conditions listed “with” diabetes in the Index. Key examples:

• Diabetes + CKD = diabetic CKD (E11.22) — no explicit “caused by diabetes” statement needed
• Diabetes + neuropathy = diabetic neuropathy (E11.4x)
• Diabetes + retinopathy = diabetic retinopathy (E11.3xx)
• Diabetes + periodontal disease = diabetic periodontal disease (E11.630)

However, the provider must not document that the condition is NOT related to diabetes. If the provider explicitly states the conditions are unrelated, do not apply the “with” convention.

I.C.4.a.5 — Hyperglycemia and Hypoglycemia: “Uncontrolled” and “poorly controlled” are not valid standalone ICD-10-CM concepts for diabetes. Per FY2026 guidelines, assign E1x.65 for documented hyperglycemia or E1x.64x (with or without coma) for documented hypoglycemia. Coders should query providers for the specific manifestation when vague control language is used.

Gestational Diabetes (O24.x): Gestational DM is classified in O24.4xx (diet-controlled O24.410, oral drug-controlled O24.420, insulin-controlled O24.430, combination-controlled O24.435, uncontrolled O24.439). Assign O24.92x for unspecified diabetes mellitus in pregnancy when the type cannot be confirmed. Do NOT assign codes from E08–E13 for gestational DM unless the patient has pre-existing DM entering pregnancy (O24.0xx for pre-existing T1, O24.1xx for pre-existing T2).

🔢 9. ICD-10-CM Code Set (FY2026)

The following tables provide the full operative code set for FY2026 effective October 1, 2025. All codes verified against the CDC/NCHS ICD-10-CM FY2026 Tabular List.

E08 — Diabetes Mellitus Due to Underlying Condition

E09 — Drug or Chemical Induced Diabetes Mellitus

E10 — Type 1 Diabetes Mellitus

E11 — Type 2 Diabetes Mellitus (Most Common)

E13 — Other Specified Diabetes Mellitus

Gestational Diabetes & Additional Codes

🔎 10. Indexing

The ICD-10-CM Alphabetic Index is the starting point for all diabetes coding. Key lookup pathways:

• Main term “Diabetes, diabetic”: Sub-terms include “Type 1,” “Type 2,” “due to underlying condition,” “drug-induced,” “gestational.” Under each type, sub-sub-terms list every complication — e.g., “with / kidney complications / chronic kidney disease.”
• “With” convention in the Index: Sub-terms listed under “with” in the diabetes entry do NOT require explicit provider linkage. For example, “Diabetes, diabetic / Type 2 / with / chronic kidney disease” maps directly to E11.22 based on the index structure.
• Searching by complication first: “Neuropathy, diabetic” → redirects to “Diabetes, diabetic / with / neurological complications.” “Retinopathy, diabetic” → redirects to “Diabetes, diabetic / with / ophthalmic complications.”
• Insulin dependence lookup: “Z79.4” is found under “Long-term (current) drug therapy / insulin.” This code is critical for risk adjustment documentation.
• Gestational DM: Index under “Diabetes, gestational” → O24.4xx series. Pre-existing diabetes in pregnancy → “Pregnancy / complicated by / diabetes / pre-existing.”

🏥 11. CPT (2026)

Diabetes management involves multiple clinical service types. The following CPT codes are most frequently used for FY2026 reporting, verified against AMA CPT 2026 and CMS Physician Fee Schedule guidance.

🧾 12. HCPCS (2026)

HCPCS Level II codes are primarily used for durable medical equipment (DME), supplies, and certain outpatient services related to diabetes management. The following are operative for CY2026, verified against CMS HCPCS Level II 2026.

📚 13. AHA Coding Clinic (Recent Guidance)

The AHA Coding Clinic is the authoritative secondary source for ICD-10-CM coding guidance. The following represents key Coding Clinic positions relevant to diabetes mellitus as of the most recent published guidance (4Q 2023 through 2025):

Long-Term Insulin Use with Type 2 Diabetes

Coding Clinic has consistently affirmed that when a Type 2 diabetic patient uses long-term insulin, coders must assign Z79.4 (long-term current use of insulin) as an additional code. This is not optional — omitting Z79.4 understates the complexity of management, may affect risk adjustment (HCC documentation support), and misrepresents the patient’s treatment regimen. This guidance was reinforced through IKS Health coding analysis citing Coding Clinic 3Q 2019, Page 37 and remains active in FY2026 guidelines.

“With” Convention — Automatic Presumptive Linkage

Coding Clinic has clarified that the “with” convention in ICD-10-CM Guideline I.A.15 establishes a presumptive causal relationship based on the Alphabetic Index structure alone — no explicit documentation of causation is required from the provider. This applies to all conditions listed “with” diabetes in the Index (CKD, neuropathy, retinopathy, etc.). Providers need not write “diabetic CKD” — the presence of CKD and diabetes in the same record, without explicit denial of the relationship, is sufficient to assign E11.22. Coding Clinic has also noted that this convention does NOT override explicit provider documentation to the contrary.

Steroid-Induced (Drug-Induced) Diabetes — HCC Impact

Coding Clinic guidance on E09 (drug/chemical-induced DM) requires sequencing E09.x FIRST, followed by the adverse effect T-code (e.g., T38.0x5A for initial encounter with corticosteroid adverse effect). Coders must be aware that under HCC v28 (fully operative 2026), ALL E09 codes have been removed from the risk adjustment model — steroid-induced diabetes no longer generates HCC RAF weight regardless of complications documented.

Diabetic Neuropathy Specificity

Recent Coding Clinic guidance emphasizes the importance of capturing the specific type of neuropathy when documentation supports it: polyneuropathy (E11.42), autonomic neuropathy (E11.43), mononeuropathy (E11.41), or amyotrophy (E11.44). Unspecified diabetic neuropathy (E11.40) should be queried for further specificity, as more specific codes may affect MS-DRG and clinical quality metrics.

Diabetes in Remission (E11.A)

A newer code, E11.A (Type 2 DM without complications, in remission), requires explicit provider documentation using the word “remission.” This code is appropriate for patients who have achieved sustained euglycemia through significant weight loss (bariatric surgery, intensive lifestyle intervention) and have discontinued all antidiabetic medications. Coders should NOT apply this code without provider documentation, and should query when the record suggests DM may be in remission based on clinical indicators alone.

💰 14. HCC / Risk Adjustment (v28)

Diabetes mellitus is among the most significant conditions in Medicare Advantage (MA) risk adjustment under CMS-HCC Model V28, which became fully operative for payment year 2026 (eliminating the 2024–2025 V24/V28 blend). Understanding V28’s diabetes hierarchy is critical for risk-accurate documentation.

V28 Diabetes HCC Hierarchy (4 Tiers)

Per AAFP analysis of HCC V28 changes and CHI Health Partners HCC V28 training:

HCC Mapping Cross-Reference Table

✍️ 15. CDI Query Templates

All CDI queries must comply with ACDIS/AHIMA CDI professional practice standards: queries must be non-leading, offer multiple clinically reasonable response options (including “clinically undetermined”), and not suggest a specific code or reimbursement-driven answer.

🧑‍⚕️ 16. Treatments (Clinical)

This section provides a clinical treatment overview consistent with ADA Standards of Care in Diabetes—2026 for context to support CDI and coding accuracy assessments.

Lifestyle and Behavioral Interventions

• Medical nutrition therapy (MNT): Low-carbohydrate, Mediterranean, DASH, or plate-method eating patterns; individualized caloric targets; no single diet mandated per ADA 2026
• Physical activity: ≥150 min/week moderate-intensity aerobic activity; resistance training 2–3×/week; reduce prolonged sitting
• Weight management: 5–10% weight loss in T2DM improves glycemic control; 15–20% may induce remission; GLP-1 agonists and tirzepatide achieve 15–22% weight loss in clinical trials
• DSMES (Diabetes Self-Management Education and Support): ADA 2026 Recommendation 5.2 — provide DSMES at diagnosis, annually, when complications develop, and at life transitions; billed via G0108/G0109
• Smoking cessation: Critical — smoking dramatically accelerates all DM macrovascular and microvascular complications

Pharmacologic Targets (ADA 2026)

• A1C target: <7% for most non-pregnant adults; <6.5% if achievable without significant hypoglycemia; <8% for older adults with multiple comorbidities or limited life expectancy
• Blood pressure: <130/80 mmHg for most DM patients; ACE inhibitors/ARBs preferred with proteinuria or CKD
• Lipids: Moderate-intensity statin for all DM patients 40–75 years; high-intensity statin with ASCVD or high risk
• Preferred agents with established CVD: SGLT-2 inhibitors (empagliflozin, dapagliflozin) or GLP-1 agonists (semaglutide, liraglutide) as add-on to metformin per ADA 2026 algorithm
• Preferred with CKD (eGFR >20): Finerenone (non-steroidal MRA), SGLT-2 inhibitors — per ADA 2026 updated CKD recommendations

Monitoring Technologies

• Continuous glucose monitoring (CGM): ADA 2026 Recommendation 13.5 — recommended for all Type 1 DM; recommended for Type 2 on insulin therapy; CGM improves A1C and reduces hypoglycemia
• Insulin pump (CSII): Preferred for Type 1 patients on multiple daily injections failing glycemic targets; closed-loop (artificial pancreas) systems increasingly covered
• Self-monitoring of blood glucose (SMBG): Fingerstick BG monitoring; still appropriate for patients not on CGM, especially on insulin

Inpatient Diabetes Management

Per ADA 2026 Section 16 (Diabetes Care in the Hospital), insulin is the preferred agent for managing hyperglycemia in hospitalized patients (target BG 140–180 mg/dL per ICU guidelines; 100–180 mg/dL general ward). MS-DRG assignment for inpatient DM admissions (DKA, HHS, hypoglycemia) is driven by principal diagnosis — ensure the acute complication is sequenced appropriately as PDx when it is the reason for admission.

🎓 17. Patient Education / Summary

The following summary is intended for use in patient-facing materials, care coordination notes, and health literacy communications consistent with ADA 2026 Standards of Care, Section 5 (Facilitating Positive Health Behaviors).

What Is Diabetes?

Diabetes mellitus is a lifelong condition in which the body cannot properly use or make insulin — the hormone that helps blood sugar (glucose) enter your cells for energy. When glucose builds up in the bloodstream, it damages blood vessels and nerves throughout the body over time. The good news: with proper management, people with diabetes can live long, healthy, full lives.

Types of Diabetes

• Type 1: The immune system destroys insulin-producing cells. Requires insulin therapy every day. Often diagnosed in children and young adults, but can occur at any age.
• Type 2: The body doesn’t use insulin well. Often related to weight, activity level, and family history. Usually managed with lifestyle changes, pills, and/or injectable medications. May eventually require insulin.
• Gestational diabetes: Develops during pregnancy. Usually resolves after delivery but increases risk of Type 2 diabetes later in life.

Managing Your Diabetes — Key Actions

• Check your blood sugar as directed by your healthcare team — using a glucometer or continuous glucose monitor (CGM)
• Take your medications every day as prescribed — insulin, pills, or injectable medications
• Eat healthy foods — focus on vegetables, whole grains, lean proteins; limit sugary beverages and refined carbohydrates
• Stay active — aim for at least 30 minutes of moderate exercise (such as walking) most days of the week
• Keep appointments — A1C test every 3 months if not at goal; annual eye exam (dilated or retinal imaging); annual foot exam; annual kidney function test (urine microalbumin, creatinine)
• Know the warning signs: High blood sugar (thirst, frequent urination, fatigue, blurry vision); Low blood sugar (shakiness, sweating, confusion — treat with 15 grams of fast-acting carbohydrate)

Annual Preventive Screenings for Diabetic Patients (ADA 2026)

This guide is intended for certified professional coders, CDI specialists, CRC practitioners, and CPMA auditors. All ICD-10-CM codes reflect FY2026 NCHS/CMS tabular list (effective October 1, 2025). HCC weights reflect CMS-HCC Model V28 fully operative as of payment year 2026. CPT codes reflect AMA CPT 2026. HCPCS codes reflect CMS HCPCS Level II CY2026. Clinical standards reflect ADA Standards of Care in Diabetes—2026.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)